Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dasatinib

dasatinib

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dasatinib

79 trials tracked of dasatinib: 7 in phase 3 or 4 and 2 with published results. The most-cited published study has 256 citations.

79Trials tracked
7Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 64 Phase 1 5 Other / NA 3
  1. Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 256 cited
  2. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 87 cited
  3. Phase 4 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed
  4. Phase 3 A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Completed
  5. Phase 3 Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer Completed
  6. Phase 3 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML Completed
Show 44 more trials
  1. Phase 3 Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML Completed
  2. Phase 2 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed
  3. Phase 2 Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis Completed
  4. Phase 2 A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed
  5. Phase 2 Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia Completed
  6. Phase 2 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma Completed
  7. Phase 2 Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib Completed
  8. Phase 2 Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) Completed
  9. Phase 2 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma Completed
  10. Phase 2 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed
  11. Phase 2 Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Completed
  12. Phase 2 Phase II Dasatinib Study in Advanced Breast Cancer Completed
  13. Phase 2 Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Completed
  14. Phase 2 Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer Completed
  15. Phase 2 Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects Completed
  16. Phase 2 Treatment of Adult Ph+ LAL With BMS-354825 Completed
  17. Phase 2 A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer Completed
  18. Phase 2 Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer Completed
  19. Phase 2 Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  20. Phase 2 Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  21. Phase 2 Trial of Dasatinib in Advanced Sarcomas Completed
  22. Phase 2 Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma Completed
  23. Phase 2 S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone Completed
  24. Phase 2 Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Completed
  25. Phase 2 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Completed
  26. Phase 2 Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Completed
  27. Phase 2 Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer Completed
  28. Phase 2 Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Completed
  29. Phase 2 Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib Completed
  30. Phase 2 Rollover Study of BMS-354825 in Patients With CML and Ph+ALL Completed
  31. Phase 2 Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies Completed
  32. Phase 2 Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer Completed
  33. Phase 2 Dasatinib in Treating Patients With Metastatic Pancreatic Cancer Completed
  34. Phase 2 A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib Completed
  35. Phase 2 Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer Completed
  36. Phase 2 A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Completed
  37. Phase 2 Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response Completed
  38. Phase 2 Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease Completed
  39. Phase 2 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed
  40. Phase 2 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed
  41. Phase 2 Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer Completed
  42. Phase 2 Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer Completed
  43. Phase 2 Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib Completed
  44. Phase 2 Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed

Showing the 50 most-cited and recently-updated of 79 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML
Hematology Meta-analysis
Dasatinib 50 mg maintains efficacy while reducing pleural effusion and thrombocytopenia in CP-CML Lower Dasatinib Dose May Improve Tolerability for Leukemia Patients
This meta-analysis of 7 nonoverlapping reports compared dasatinib 50 mg and 100 mg in adults with chronic-phase chronic myeloid leukemia. Th…
A lower daily dose of dasatinib may offer similar effectiveness with fewer side effects for adults with chronic-phase chronic myeloid leukem…
Sep 1, 2026
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients
Hematology Phase III
6-month IS value predicts MR4.5 attainment and TKI discontinuation eligibility in CML patients Trial Shows Early Markers Predict Success in Chronic Myeloid Leukemia
This observational study of 431 patients with chronic myeloid leukemia (CML) on second-generation TKIs found that the 6-month IS value is a …
New data from a Phase 3 trial shows that early markers can help predict which patients with chronic myeloid leukemia may reach specific trea…
Aug 25, 2026
Senolytics like dasatinib and quercetin show promise for improving skeletal parameters in osteoporosis models
Diabetes & Endocrinology Sys. Review
Senolytics like dasatinib and quercetin show promise for improving skeletal parameters in osteoporosis models Senolytics Show Potential for Improving Bone Health in Osteoporosis
This narrative review synthesizes preclinical and early clinical evidence regarding senolytics including dasatinib, quercetin, and fisetin f…
New research explores how senolytics like dasatinib and quercetin may reduce inflammation and improve bone health in patients with osteoporo…
Frontiers Aug 25, 2026
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
Oncology
Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
medRxiv Apr 24, 2026
Dasatinib Added to Intensive Chemotherapy Fails to Improve Survival in CBF-AML
Oncology RCT
Dasatinib Added to Intensive Chemotherapy Fails to Improve Survival in CBF-AML Adding Dasatinib to Chemo Does Not Help CBF-AML Patients
A phase 3 randomized trial in 202 adults with core-binding factor acute myeloid leukemia (CBF-AML) found adding dasatinib to intensive chemo…
Adding dasatinib to standard chemotherapy did not improve survival for adults with core-binding factor acute myeloid leukemia and increased …
Blood Apr 10, 2026
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04
Hematology Phase II
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04 Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Apr 8, 2026
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty
Infectious Disease Phase II
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty Can a New Drug Combination Help Older Adults with HIV Regain Strength?
Phase II trial of dasatinib and quercetin (D+Q) in 82 HIV+ frail/prefrail adults shows potential in improving gait speed.
A new trial tests if two drugs help older adults with HIV regain strength and walk better after years of frailty.
CT.gov Mar 27, 2026